P A Zucali1, M Perrino2, E Lorenzi2, G L Ceresoli3, F De Vincenzo2, M Simonelli2, L Gianoncelli2, R De Sanctis2, L Giordano4, A Santoro2. 1. Department of Medical Oncology and Hematology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy. Electronic address: paolo.zucali@humanitas.it. 2. Department of Medical Oncology and Hematology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy. 3. Department of Medical Oncology and Hematology, Istituto Humanitas Gavazzeni, Bergamo, Italy. 4. Biostatistic Unit, Humanitas Clinical and Research Center, Rozzano, Milan, Italy.
Abstract
BACKGROUND: Pemetrexed-platinum chemotherapy is the standard first-line treatment of unresectable malignant pleural mesothelioma (MPM). At progression, patients are generally selected to experimental trials, when available, or, in every-day clinical practice, they are offered second-line chemotherapy. The optimal treatment has not yet been defined. The aim of this retrospective, single-center study was to evaluate the activity and toxicity of vinorelbine administered to a consecutive series of pemetrexed-pretreated MPM patients. METHODS: Vinorelbine 25 mg/m(2) was administered intravenously as a single agent on days 1, 8 every three weeks, either as second-line (2L) or further-line (>2L) therapy. Treatment was repeated for a maximum of 6 cycles, until progression, or unacceptable toxicity. RESULTS: Fifty-nine patients were included in this analysis. Vinorelbine was given to 34 patients as 2L, and to 25 as > 2L treatment. The median age was 69 years (range 45-80). Forty-two patients (71.2%) had a good EORTC prognostic score. Partial response was observed in 9 (15.2%) cases, stable disease in 20 (33.9%). The overall disease control rate (DCR) was 49.1%. Median progression-free survival (PFS) and overall survival (OS) were 2.3 and 6.2 months, respectively. ECOG performance status (PS) (HR(0 vs. 1-2) 0.50; 95%CI: 0.3-0.8; p = 0.014) and PFS ≥ 6 months following first-line (FL) chemotherapy (HR(FL-PFS>6 ms vs. <6 ms) 0.50; 95%CI: 0.3-0.9; p = 0.031) were significantly associated to OS in multivariate analysis. No difference was observed in terms of DCR, PFS, and OS in relation to age, histology, sex, line of vinorelbine therapy, or response to FL treatment. Hematological toxicity was acceptable, with grade 3/4 neutropenia occurring in 5 (8.4%) patients, and there were no cases of febrile neutropenia. The main non-hematological toxicities were grade 2 fatigue in 17 (28.8%) and constipation in 7 (11.8%) patients. CONCLUSIONS: Vinorelbine was moderately active in pemetrexed-pretreated MPM patients, with an acceptable toxicity profile, particularly in patients with ECOG-PS0 and FL-PFS ≥ 6 months.
BACKGROUND:Pemetrexed-platinum chemotherapy is the standard first-line treatment of unresectable malignant pleural mesothelioma (MPM). At progression, patients are generally selected to experimental trials, when available, or, in every-day clinical practice, they are offered second-line chemotherapy. The optimal treatment has not yet been defined. The aim of this retrospective, single-center study was to evaluate the activity and toxicity of vinorelbine administered to a consecutive series of pemetrexed-pretreated MPM patients. METHODS:Vinorelbine 25 mg/m(2) was administered intravenously as a single agent on days 1, 8 every three weeks, either as second-line (2L) or further-line (>2L) therapy. Treatment was repeated for a maximum of 6 cycles, until progression, or unacceptable toxicity. RESULTS: Fifty-nine patients were included in this analysis. Vinorelbine was given to 34 patients as 2L, and to 25 as > 2L treatment. The median age was 69 years (range 45-80). Forty-two patients (71.2%) had a good EORTC prognostic score. Partial response was observed in 9 (15.2%) cases, stable disease in 20 (33.9%). The overall disease control rate (DCR) was 49.1%. Median progression-free survival (PFS) and overall survival (OS) were 2.3 and 6.2 months, respectively. ECOG performance status (PS) (HR(0 vs. 1-2) 0.50; 95%CI: 0.3-0.8; p = 0.014) and PFS ≥ 6 months following first-line (FL) chemotherapy (HR(FL-PFS>6 ms vs. <6 ms) 0.50; 95%CI: 0.3-0.9; p = 0.031) were significantly associated to OS in multivariate analysis. No difference was observed in terms of DCR, PFS, and OS in relation to age, histology, sex, line of vinorelbine therapy, or response to FL treatment. Hematological toxicity was acceptable, with grade 3/4 neutropenia occurring in 5 (8.4%) patients, and there were no cases of febrile neutropenia. The main non-hematological toxicities were grade 2 fatigue in 17 (28.8%) and constipation in 7 (11.8%) patients. CONCLUSIONS:Vinorelbine was moderately active in pemetrexed-pretreated MPM patients, with an acceptable toxicity profile, particularly in patients with ECOG-PS0 and FL-PFS ≥ 6 months.
Authors: Xabier Mielgo-Rubio; Ana Cardeña Gutiérrez; Verónica Sotelo Peña; Maria Virginia Sánchez Becerra; Andrea María González López; Adriana Rosero; Juan Carlos Trujillo-Reyes; Felipe Couñago Journal: World J Clin Oncol Date: 2022-04-24
Authors: Marjorie G Zauderer; Samantha L Kass; Kaitlin Woo; Camelia S Sima; Michelle S Ginsberg; Lee M Krug Journal: Lung Cancer Date: 2014-03-14 Impact factor: 5.705
Authors: M Mark; S Rusakiewicz; M Früh; S Hayoz; F Grosso; M Pless; P Zucali; G L Ceresoli; A Maconi; M Schneider; P Froesch; D Tarussio; F Benedetti; J Dagher; L Kandalaft; R von Moos; S Tissot-Renaud; S Schmid; Y Metaxas Journal: ESMO Open Date: 2022-04-12
Authors: C Raynaud; L Greillier; J Mazieres; I Monnet; B Mastroianni; G Robinet; G Fraboulet; A Dixmier; H Berard; R Lamy; J Letreut; H Lena; G Oliviero; S Botta; A Vergnenegre; I Borget; C Chouaid Journal: BMC Cancer Date: 2015-11-06 Impact factor: 4.430
Authors: Xavier Elharrar; Dominique Barbolosi; Joseph Ciccolini; Christophe Meille; Christian Faivre; Bruno Lacarelle; Nicolas André; Fabrice Barlesi Journal: BMC Cancer Date: 2016-04-20 Impact factor: 4.430